Retagliptin

Retagliptin
Identifiers
	IUPAC name Methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate;
CAS Number	1174122-54-3;
PubChem CID	44193830;
DrugBank	DB14898;
ChemSpider	57583801;
UNII	328C4R3P9L;
ChEMBL	ChEMBL4297435;
Chemical and physical data
Formula	C19H18F6N4O3
Molar mass	464.368 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C1=C2CN(CCN2C(=N1)C(F)(F)F)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N;
	InChI InChI=1S/C19H18F6N4O3/c1-32-17(31)16-14-8-28(2-3-29(14)18(27-16)19(23,24)25)15(30)6-10(26)4-9-5-12(21)13(22)7-11(9)20/h5,7,10H,2-4,6,8,26H2,1H3/t10-/m1/s1; Key:WIIAMRXFUJLYEF-SNVBAGLBSA-N;

Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.^[1]^[2]^[3]

Quick facts Identifiers, CAS Number ...

In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.^[4]

References